A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker

Ma, Chenkai; Nguyen, Huy; Luwor, Rodney B; Stylli, Stanley S.; Gogos, Andrew; Paradiso, Lucy; Kaye, Andrew H.; Morokoff, Andrew

doi:10.1371/journal.pone.0189452

Cited by 37 publications

(33 citation statements)

References 46 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the major shortcoming of using blood-based miRNA for CRC screening is the detection specificity. This is because miRNAs might arise from other cancer(s) [64,65], depression [66], and virus infection(s) [67,68]. Therefore, faecal-based miRNA detection may be an alternative option [57,59,60,69].…”

Section: Screening Tools Under Developmentmentioning

confidence: 99%

Non-Invasive Colorectal Cancer Screening: An Overview

Tepus¹,

Yau²

2020

Gastrointest Tumors

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) follows a protracted stepwise progression, from benign adenomas to malignant adenocarcinomas. If detected early, 90% of deaths are preventable. However, CRC is asymptomatic in its early-stage and arises sporadically within the population. Therefore, CRC screening is a public health priority. Summary: Faecal immunochemical test (FIT) is gradually replacing guaiac faecal occult blood test and is now the most commonly used screening tool for CRC screening program globally. However, FIT is still limited by the haemoglobin degradation and the intermittent bleeding patterns, so that one in four CRC cases are still diagnosed in a late stage, leading to poor prognosis. A multi-target stool DNA test (Cologuard, a combination of NDRG4 and BMP3 DNA methylation, KRAS mutations, and haemoglobin) and a plasma SEPT9 DNA methylation test (Epi proColon) are non-invasive tools also approved by the US FDA, but those screening approaches are not cost-effective, and the detection accuracies remain unsatisfactory. In addition to the approved tests, faecal-/bloodbased microRNA and CRC-related gut microbiome screening markers are under development, with work ongoing to find the best combination of molecular biomarkers which maximise the screening sensitivity and specificity. Key Message: Maximising the detection accuracy with a cost-effective approach for non-invasive CRC screening is urgently needed to further reduce the incidence of CRC and associated mortality rates.

show abstract

Section: Screening Tools Under Developmentmentioning

confidence: 99%

Non-Invasive Colorectal Cancer Screening: An Overview

Tepus¹,

Yau²

2020

Gastrointest Tumors

View full text Add to dashboard Cite

show abstract

“…There have been multiple studies examining 'free-circulating' miRNAs in glioma patients with varying success. A recent meta-analysis of these studies found the specificity and sensitivity of circulating miRNAs was 0.87 and 0.86, respectively, while noting the large heterogeneity of circulating miRNAs within the included studies [17]. The heterogeneity is likely due to differences in data normalization used in qRT-PCR studies, with no universally accepted endogenous housekeeping control [17].…”

Section: Mirnas Dysregulated In Idh-mutant Grade Ii-iii Gliomas Provimentioning

confidence: 99%

“…A recent meta-analysis of these studies found the specificity and sensitivity of circulating miRNAs was 0.87 and 0.86, respectively, while noting the large heterogeneity of circulating miRNAs within the included studies [17]. The heterogeneity is likely due to differences in data normalization used in qRT-PCR studies, with no universally accepted endogenous housekeeping control [17]. Interestingly, the majority of miRNAs identified in our exosomal signature have not been previously identified in 'free-circulating' studies.…”

Section: Mirnas Dysregulated In Idh-mutant Grade Ii-iii Gliomas Provimentioning

confidence: 99%

Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis

Ebrahimkhani

Vafaee

Hallal

et al. 2018

Preprint

View full text Add to dashboard Cite

243; References, 36; Figure legends, 533. 32 ABSTRACT 34 Exosomes are nano-sized extracellular vesicles released by many cells that contain 35 molecules characteristic of their cell-of-origin, including microRNA. Exosomes released 36 by glioblastoma cross the blood-brain-barrier into the peripheral circulation, and carry 37 molecular cargo distinct to that of 'free-circulating' miRNA. In this pilot study, serum 38 exosomal-microRNAs were isolated from glioblastoma (n=12) patients and analyzed 39 using unbiased deep sequencing. Results were compared to sera from age-and gender-40 matched healthy controls, and to grades II-III (n=10) glioma patients. Significant 41 differentially expressed microRNAs were identified, and the predictive power of 42 individual and subsets of microRNAs were tested using univariate and multivariate 43 analyses. Additional sera from glioblastoma patients (n=4) and independent sets of 44 healthy (n=9) and non-glioma (n=10) controls were used to further test the specificity and 45 predictive power of this unique exosomal-microRNA signature. Twenty-six microRNAs 46 were differentially expressed in serum exosomes from glioblastoma patients' relative to 47 59

show abstract

“…These characteristics of miRNAs make them potentially useful diagnostic, prognostic, and predictive biomarkers for cancer research (12). A few biomarkers studies have demonstrated early diagnosis and progression could be predicted by tissue or blood miRNAs expression (13).…”

Section: Introductionmentioning

confidence: 99%

Machine Learning Identifies the miR-196b and miR-34c-5p as the Chemotherapy Response Biomarkers of Lung Adenocarcinoma

Lan¹,

Xue²,

Chen³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgrooundLung adenocarcinoma is one of the most common malignant lung cancers. Although platinum-based chemotherapy is the first-line adjuvant treatment for middle and late stage lung adenocarcinoma, the response of chemotherapy varies between patients. Moreover, there are no effective biomarkers that could predict chemotherapy response in clinical practice. MiRNAs that are stable in all types of body fluid have demonstrated their diagnostic and prognostic capacity in variety of cancers. Here, we utilized three different machine learning algorithms to identify miRNA signatures specific to chemotherapy response in lung cancer. MethodsThrough a public dataset, a panel of miRNAs for response to chemotherapy was identified by Machine Learning. The predictive capacity was determined by the receiver operation curve. A cohort involving 30 patients with lung adenocarcinoma was utilized for validate the miRNA panel. ResultsMachine Learnings identified five chemotherapy response featured miRNAs (miR-196b, miR-34c-5p, miR-181b, miR-27b and miR-26a). The putative targets of these miRNA signatures are enriched in the biosynthesis. Two of these miRNA signatures (miR-196b and miR-34c-5p) were validated for their chemotherapy response prediction in our 30 serum samples of lung adenocarcinoma with the accuracy of 0.90 and 0.93, respectively. ConclusionsOur study demonstrates circulating miRNA could potentially be predictive biomarker for chemotherapy response in lung adenocarcinoma.

show abstract

A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker

Cited by 37 publications

References 46 publications

Non-Invasive Colorectal Cancer Screening: An Overview

Non-Invasive Colorectal Cancer Screening: An Overview

Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis

Machine Learning Identifies the miR-196b and miR-34c-5p as the Chemotherapy Response Biomarkers of Lung Adenocarcinoma

Contact Info

Product

Resources

About